SCHEMBL20599149

SCHEMBL20599149

CCOC(=O)c1cc2c(s1)-c1ccc(F)cc1NCC2

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 10/20 0.57
ALDH1A1 P00352 6/20 0.57
L3MBTL1 Q9Y468 5/20 0.57
TDP1 Q9NUW8 4/20 0.57
HPGD P15428 3/20 0.57
MAPK14 Q16539 1/20 0.49
GAA P10253 5/20 0.43
MAPT P10636 4/20 0.41
GLA P06280 3/20 0.41
RAB9A P51151 3/20 0.41
ATM Q13315 2/20 0.41
NPC1 O15118 2/20 0.41
MEN1 O00255 1/20 0.39
LMNA P02545 1/20 0.39
POLB P06746 1/20 0.39
DNMT1 P26358 1/20 0.39
APEX1 P27695 1/20 0.39
APOBEC3A P31941 1/20 0.39
RECQL P46063 1/20 0.39
BLM P54132 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20619706 0.88 KDM4E (0.56) KDM4EALDH1A1L3MBTL1TDP1HPGD
SCHEMBL20619601 0.87 KDM4E (0.57) KDM4EALDH1A1L3MBTL1TDP1HPGD
SCHEMBL11910402 0.85 KDM4E (0.70) KDM4EALDH1A1L3MBTL1TDP1HPGD
Bromide SCHEMBL19689589 0.84 KDM4E (0.69) KDM4EALDH1A1L3MBTL1TDP1HPGD
Hydrochloric Acid SCHEMBL19689605 0.84 KDM4E (0.69) KDM4EALDH1A1L3MBTL1TDP1HPGD
SCHEMBL20614680 0.83 ALDH1A1 (0.57) KDM4EALDH1A1L3MBTL1TDP1HPGD
SCHEMBL20614930 0.80 ALDH1A1 (0.57) KDM4EALDH1A1L3MBTL1TDP1HPGD
SCHEMBL20622242 0.80 ALDH1A1 (0.61) KDM4EALDH1A1L3MBTL1TDP1HPGD
SCHEMBL19454421 0.79 ALDH1A1 (0.54) KDM4EALDH1A1L3MBTL1TDP1HPGD
SCHEMBL21471796 0.78 MAPK14 (0.47) KDM4EALDH1A1L3MBTL1HPGDMAPK14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11091501-B2 Heterocyclic compounds as RSV inhibitors ENANTA PHARMACEUTICALS, INC. (US) 2021-08-17 US disclosed
US-11091501-B2 Heterocyclic compounds as RSV inhibitors ENANTA PHARMACEUTICALS, INC. (US) 2021-08-17 US disclosed
US-10975094-B2 Heterocyclic compounds as RSV inhibitors ENANTA PHARMACEUTICALS, INC. (US) 2021-04-13 US disclosed
US-20190315766-A1 HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS ENANTA PHARMACEUTICALS, INC. 2019-10-17 US disclosed
WO-2019006295-A1 HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS ENANTA PHARMACEUTICALS, INC. (US) 2019-01-03 WO disclosed
US-20190002479-A1 HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS ENANTA PHARMACEUTICALS, INC. 2019-01-03 US disclosed
US-20190002479-A1 HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS ENANTA PHARMACEUTICALS, INC. 2019-01-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10975094-B2 Heterocyclic compounds as RSV inhibitors SIRT1, FURIN, SIRT5 KDM4E 1288/4885ALDH1A1 701/4885L3MBTL1 4787/4885
US-20190315766-A1 HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS SIRT1, FURIN, SIRT5 KDM4E 1288/4885ALDH1A1 701/4885L3MBTL1 4787/4885
US-11091501-B2 Heterocyclic compounds as RSV inhibitors SIRT1, FURIN, SIRT5 KDM4E 1342/4885ALDH1A1 721/4885L3MBTL1 4774/4885
US-20190002479-A1 HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS SIRT1, FURIN, SIRT5 KDM4E 1342/4885ALDH1A1 721/4885L3MBTL1 4774/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.